Clinical trials have explored the safety profile of AOD and reported few adverse effects, such as insulin resistance or unwanted muscle growth, which are typically associated with traditional GH therapies (2)
Meanwhile, FGFR2c/3c activation in hepatocytes inhibits de novo lipogenesis and limits lipid accumulation
How long does a BPC-157 protocol last
Its unclear what will happen when kids have to take this drug for the rest of their lives and how that could potentially affect their physical and mental health
Second, retatrutide results demonstrate a durability advantage over existing GLP-1 compounds
Ben David A, Papir Y, Hazan O, Redelman M, Diamant E, Barnea A, et al